First-in-human, phase I/IIa clinical study of the peptidase potentiated alkylator melflufen administered every three weeks to patients with advanced solid tumor malignancies

@article{Berglund2015FirstinhumanPI,
  title={First-in-human, phase I/IIa clinical study of the peptidase potentiated alkylator melflufen administered every three weeks to patients with advanced solid tumor malignancies},
  author={{\AA}. Berglund and A. Ull{\'e}n and A. Lisyanskaya and S. Orlov and H. Hagberg and B. Tholander and R. Lewensohn and P. Nygren and J. Spira and J. Harmenberg and M. Jerling and C. Alvfors and Magnus Ringbom and E. Nordström and Karin S{\"o}derlind and J. Gullbo},
  journal={Investigational New Drugs},
  year={2015},
  volume={33},
  pages={1232-1241}
}
SummaryPurpose Melflufen (melphalan flufenamide, previously designated J1) is an optimized and targeted derivative of melphalan, hydrolyzed by aminopeptidases overexpressed in tumor cells resulting in selective release and trapping of melphalan, and enhanced activity in preclinical models. Methods This was a prospective, single-armed, open-label, first-in-human, dose-finding phase I/IIa study in 45 adult patients with advanced and progressive solid tumors without standard treatment options… Expand
Melflufen: A Peptide–Drug Conjugate for the Treatment of Multiple Myeloma
TLDR
Melflufen, with its novel mechanism of action, has the potential to provide clinically meaningful benefits to patients with relapsed/refractory multiple myeloma, including those with high unmet needs. Expand
A Phase I/II Study of Evofosfamide, A Hypoxia-activated Prodrug with or without Bortezomib in Subjects with Relapsed/Refractory Multiple Myeloma
TLDR
The presence of hypoxia in the diseased bone marrow presents a new therapeutic target for multiple myeloma and evofosfamide can be administered at 340 mg/m2 twice a week with or without bortezomib. Expand
Spotlight on Melphalan Flufenamide: An Up-and-Coming Therapy for the Treatment of Myeloma
TLDR
Melflufen plus dexamethasone as a doublet, and in combination with other novel drugs, has the potential to be beneficial for a broad range of patients with relapsed/refractory multiple myeloma in third- or even in second-line therapy. Expand
Melflufen plus dexamethasone in relapsed and refractory multiple myeloma (O-12-M1): a multicentre, international, open-label, phase 1-2 study.
TLDR
A phase 1-2 study of melflufen and dexamethasone in patients with relapsed and refractory multiple myeloma to determine the maximum tolerated dose and to investigate its safety and efficacy is completed. Expand
OCEAN: a randomized Phase III study of melphalan flufenamide + dexamethasone to treat relapsed refractory multiple myeloma.
TLDR
The rationale and design of OCEAN (NCT03151811), a randomized, head-to-head, superiority, open-label, global, Phase III study evaluating the efficacy and safety of melphalan flufenamide + dexamethasone versus pomalidomide + DexamethAsone, is described. Expand
Targeting aggressive osteosarcoma with a peptidase-enhanced cytotoxic melphalan flufenamide
TLDR
Melflufen has shown an anti-proliferative effect in HGOS ex vivo samples and cell lines, including those resistant to methotrexate, etoposide, doxorubicin, and PARP inhibitors, and this sensitivity correlated with high expression of ANPEP. Expand
In vitro and in vivo anti-leukemic activity of the peptidase-potentiated alkylator melflufen in acute myeloid leukemia
TLDR
Melflufen demonstrates high and significant preclinical activity in AML and further clinical evaluation seem warranted in this disease, as well as in a patient derived xenograft study. Expand
Melflufen - a peptidase-potentiated alkylating agent in clinical trials.
TLDR
It is hypothesized that melflufen could provide better efficacy but no more toxicity than what is achieved with melphalan, an assumption so far supported by experiences from hollow fiber and xenograft studies in rodents as well as by clinical data from patients with solid tumors and multiple myeloma. Expand
Melflufen for relapsed and refractory multiple myeloma
TLDR
Melflufen has potential to fill a gap in the myeloma treatment landscape by providing a new mechanism of action with clinically meaningful efficacy and a favorable safety profile in patients refractory to multiple novel agents. Expand
Preclinical activity of melflufen (J1) in ovarian cancer
TLDR
Results from this study support further investigations of melflufen for the treatment of peritoneal carcinomatosis from ovarian cancer, both for intravenous and intraperitoneal administration. Expand
...
1
2
...

References

SHOWING 1-10 OF 27 REFERENCES
The systemic administration of intravenous melphalan.
TLDR
In poor-prognosis patients with non-Hodgkin's lymphoma, Hodgkin's disease, multiple myeloma, or neuroblastoma, high-dose melphalan-containing regimens have yielded both high response rates and improved survival, despite considerable toxicity. Expand
In Vitro and In Vivo Antitumor Activity of a Novel Alkylating Agent, Melphalan-Flufenamide, against Multiple Myeloma Cells
TLDR
The preclinical study supports clinical evaluation of mel-flufen to enhance therapeutic potential of melphalan, overcome drug-resistance, and improve multiple myeloma patient outcome. Expand
The novel alkylating prodrug J1: diagnosis directed activity profile ex vivo and combination analyses in vitro
TLDR
The ex vivo profile of J 1 suggests that further evaluation of J1 as the alkylating agent in for example aggressive breast cancer might be of particular interest, preferentially in combination with DNA-topoisomerase II inhibitors like etoposide. Expand
Antitumor efficacy and acute toxicity of the novel dipeptide melphalanyl-p-L-fluorophenylalanine ethyl ester (J1) in vivo
TLDR
The results indicate that the promising in vitro data from the previous studies of J1 seems translatable into the in vivo situation, and at equal doses of alkylating units J1 was more active in the mouse hollow-fiber model, but showed similar general toxicity. Expand
The novel melphalan prodrug J1 inhibits neuroblastoma growth in vitro and in vivo
TLDR
The melphalan prodrug J1 is highly active in models of neuroblastoma in vitro and in vivo, encouraging further clinical development in this patient group. Expand
Melphalan and its role in the management of patients with multiple myeloma
TLDR
Thalidomide, its immunomodulatory derivative lenalidomides and the proteasome inhibitor bortezomib, in combination with oral melphalan in the elderly and with intravenous melphAlan in younger patients, are changing the traditional treatment paradigm of multiple myeloma. Expand
Population pharmacokinetics of melphalan in patients with multiple myeloma undergoing high dose therapy.
TLDR
Creatinine clearance, fat free mass and haematocrit influence total and unboundmelphalan plasma clearance, andMelphalan exposure is related to melphalan toxicity while the association with efficacy shows promising trends that will be studied further. Expand
Activity of Hydrolytic Enzymes in Tumour Cells is a Determinant for Anti-tumour Efficacy of the Melphalan Containing Prodrug J1
TLDR
The results show that the activity of the dipeptide mustards is highly dependent on intracellular hydrolysis, which result in rapid intrACEllular release of the alkylating unit in cells with high enzymatic activity. Expand
The alkylating prodrug J1 can be activated by aminopeptidase N, leading to a possible target directed release of melphalan.
TLDR
A role of APN in the activation of the melphalan prodrug J1 and subsequently, its cytotoxic effects is demonstrated and data suggest that J1 may be activated in a tumor selective manner. Expand
Drug response in a genetically engineered mouse model of multiple myeloma is predictive of clinical efficacy.
TLDR
It is predicted that combinations of standard agents, histone deacetylase inhibitors, bromodomain inhibitors, and hypoxia-activated prodrugs will demonstrate efficacy in the treatment of relapsed MM. Expand
...
1
2
3
...